Cargando…

EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1–2 signaling

BACKGROUND: Acquired chemoresistance is a major challenge in the clinical treatment of glioblastoma (GBM). Circular RNAs have been verified to play a role in tumor chemoresistance. However, the underlying mechanisms remain unclear. The aim of this study was to elucidate the potential role and molecu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Yutian, Lu, Chenfei, Zhou, Peng, Zhao, Lin, Lyu, Xiao, Yin, Jianxing, Shi, ZhuMei, You, Yongping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041353/ https://www.ncbi.nlm.nih.gov/pubmed/32926734 http://dx.doi.org/10.1093/neuonc/noaa214

Ejemplares similares

DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma
por: Lu, Chenfei, et al.
Publicado: (2020)

Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma
por: Zhang, Zhuoran, et al.
Publicado: (2019)

TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT
por: Nie, Er, et al.
Publicado: (2020)

CircDLST promotes the tumorigenesis and metastasis of gastric cancer by sponging miR-502-5p and activating the NRAS/MEK1/ERK1/2 signaling
por: Zhang, Jing, et al.
Publicado: (2019)

SP1-upregulated LBX2-AS1 promotes the progression of glioma by targeting the miR-491-5p/LIF axis
por: Li, Wentao, et al.
Publicado: (2021)

Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling
por: Bright, Michael D., et al.
Publicado: (2018)

MEK1 is required for the development of NRAS-driven leukemia
por: Nowacka, Joanna D., et al.
Publicado: (2016)

Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p
por: Yin, Jianxing, et al.
Publicado: (2021)

Correction to: CircDLST promotes the tumorigenesis and metastasis of gastric cancer by sponging miR-502-5p and activating the NRAS/MEK1/ERK1/2 signaling
por: Zhang, Jing, et al.
Publicado: (2020)

eIF5B increases ASAP1 expression to promote HCC proliferation and invasion
por: Wang, Zhen-guang, et al.
Publicado: (2016)

Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma
por: Yin, Jianxing, et al.
Publicado: (2019)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

SODD Promotes Lung Cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling
por: Bao, Fan, et al.
Publicado: (2023)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

MiR-181b suppress glioblastoma multiforme growth through inhibition of SP1-mediated glucose metabolism
por: Yin, JianXing, et al.
Publicado: (2020)

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
por: Lionetti, Marta, et al.
Publicado: (2015)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

In Vitro Testing of Voltage Indicators: Archon1, ArcLightD, ASAP1, ASAP2s, ASAP3b, Bongwoori-Pos6, BeRST1, FlicR1, and Chi-VSFP-Butterfly
por: Milosevic, Milena M., et al.
Publicado: (2020)

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015)

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
por: Queralt, Bernardo, et al.
Publicado: (2016)

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
por: Smalley, K S M, et al.
Publicado: (2007)

Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas
por: Yin, Jianxing, et al.
Publicado: (2023)

Treatment of severe Kaposiform Lymphangiomatosis positive for NRAS mutation by MEK-inhibition
por: Chowers, Guy, et al.
Publicado: (2022)

Clinicopathological Implications of ASAP1 Expression in Hepatocellular Carcinoma
por: Bang, Seongsik, et al.
Publicado: (2022)

BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53
por: Nie, Er, et al.
Publicado: (2016)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022)

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma
por: van Herpen, Carla M.L., et al.
Publicado: (2019)

Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma
por: Jacobson, B A, et al.
Publicado: (2009)

Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma
por: Ranganathan, Sarangarajan, et al.
Publicado: (2016)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

ASAP distributed analysis
por: Munro, Craig, et al.
Publicado: (2007)

Oxidized LDL Downregulates ABCA1 Expression via MEK/ERK/LXR Pathway in INS-1 Cells
por: Lyu, Jingya, et al.
Publicado: (2021)

Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
por: Han, Sheng, et al.
Publicado: (2017)

Integrin beta 4 (ITGB4) and its tyrosine-1510 phosphorylation promote pancreatic tumorigenesis and regulate the MEK1-ERK1/2 signaling pathway
por: Meng, Xiangli, et al.
Publicado: (2020)

MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
por: Borcherding, Dana C., et al.
Publicado: (2023)

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
por: Beloueche-Babari, M, et al.
Publicado: (2013)

ERK1b, a 46‐kDa ERK isoform that is differentially regulated by MEK
por: Yung, Yuval, et al.
Publicado: (2022)

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
por: Sathe, A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s6pkr9bdscof09e804ii84flor